S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
pixel
ASX:SOM

SomnoMed Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume95,124 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive SOM News and Ratings via Email

Sign-up to receive the latest news and ratings for SomnoMed and its competitors with MarketBeat's FREE daily newsletter.


About SomnoMed

SomnoMed Limited, together with its subsidiaries, produces and sells devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific Region. Its products include SomnoDent, an oral appliance for obstructive sleep apnea; and SomnoBrux, a mouthguard for the treatment of teeth grinding damage, as well as SomTabs for cleaning its devices. The company was founded in 2004 and is based in Crows Nest, Australia.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Industry
Medical Devices
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$62.71 million
Book Value
A$0.39 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












SomnoMed (ASX:SOM) Frequently Asked Questions

What stocks does MarketBeat like better than SomnoMed?

Wall Street analysts have given SomnoMed a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but SomnoMed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is SomnoMed's next earnings date?

SomnoMed is scheduled to release its next quarterly earnings announcement on Friday, October 29th 2021.
View our earnings forecast for SomnoMed
.

Who are SomnoMed's key executives?

SomnoMed's management team includes the following people:
  • Mr. Neil Verdal-Austin, CEO, MD & Director
  • Mr. Hervé Fiévet, Chief Financial Officer
  • Mr. Mark Harding, VP of Global Marketing
  • Mr. Martin Weiland, Exec. VP of Sales and Marketing - Europe
  • Mr. Matthew Conlon, Exec. VP Sales & Marketing - North America
  • Dr. Jagdeep Bijwadia, Chief Medical Officer
  • Mr. Terence A. Flitcroft, Company Sec. (Age 62)
  • Dr. Peter Spencer MBA Ph.D., MAICD, Gen. Mang. of Operations (Age 65)
  • Mr. Christopher Bedford, VP of Global Production and Product Devel.

What is SomnoMed's stock symbol?

SomnoMed trades on the ASX under the ticker symbol "SOM."

How much money does SomnoMed make?

SomnoMed has a market capitalization of $0.00 and generates $62.71 million in revenue each year.

What is SomnoMed's official website?

The official website for SomnoMed is somnomed.com.

How can I contact SomnoMed?

The company can be reached via phone at 61 2 9467 0400.


This page was last updated on 10/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.